Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.

HIVandHepatitis.com coverage by topic

CROI website

3/2/15

alt

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.

alt

Read more:

CROI 2015: HIV Care in New York City [VIDEO]

Timely linkage to HIV care increased to 76% and achievement of viral suppression within a year of starting antiretroviral treatment rose to almost 70% over the past several years in New York City, but there are still notable disparities across population subgroups and more remains to be done, according to a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation

A return to normal weight after starting antiretroviral therapy (ART) can be beneficial for very sick, underweight individuals living with HIV -- but further weight gain appears to increase markers of inflammation associated with metabolic complications and poorer survival, according to a study reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

CROI 2015: The Quest for a Cure for HIV [VIDEO]

Research towards a cure for HIV continues, despite some recent setbacks. Several investigators presented their work in a session on HIV persistence, latency reversal, and viremia rebound at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle. There is still enthusiasm in the HIV cure field, said John Mellors of the University of Pittsburgh, but progress will be slow.

alt

Read more:

CROI 2015: Week-on, Weekend-Off HIV Treatment Controls Viral Load in Young People

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on 2 days over the weekend was just as effective as daily treatment at controlling viral load in an 11-country trial of adolescents and young people, Karina Butler from Our Lady’s Children’s Hospital in Dublin reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more: